Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2019-09-20 Board/Management Inform…
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on changes in senior management positions, including promotions, retirements, and new employment agreements for executives. There is no financial data or earnings information presented, nor is it an annual or quarterly report. The primary subject is the departure and appointment of directors and officers, which aligns with announcements about changes in the company's board or senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is substantial and contains detailed agreements, supporting a confident classification.
2019-09-20 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-20 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-20 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-19 English
PRIMARY DOCUMENT
Director's Dealing
2019-09-18 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 5, 2019, by uniQure N.V. It reports the entry into a material definitive agreement, specifically an underwriting agreement for a public offering of ordinary shares. The document details the terms of the offering, including the number of shares, price, and underwriters involved. It also references a press release about the pricing of the public offering. There are no financial statements or quarterly/yearly financial results presented, nor is this a management discussion or earnings release. The primary content is about a financing event (public offering of shares) and related agreements. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2019-09-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.